At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,613 enrolled
Drug / intervention
Orforglipron +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)
In Brief
A Phase 3 clinical trial evaluating Orforglipron and Placebo for Obesity and 2 related conditions. Completed, enrolled 1,613 participants across 136 sites in 11 countries.
Detailed Summary
This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Overweight, Type 2 Diabetes
CountriesArgentina, Australia, Brazil, China, Czechia, Germany, Greece, India, Puerto Rico, South Korea, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202420252026
First PostedMay 2023
Enrollment StartJun 2023
Primary CompletionAug 2025
TodayJul 2026
First PostedMay 24, 2023
Enrollment StartJun 5, 2023
Primary CompletionAug 8, 2025
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 3.1 years ago
Interventions
Orforgliprondrug
Administered orally
Placebodrug
Administered orally